Skip to main content
. 2019 May 22;4(9):1235–1247. doi: 10.1016/j.ekir.2019.05.010

Table 3.

Treatment-emergent adverse events occurring in ≥5% of patients in either treatment group during the maintenance phase

Preferred term Epoetin alfa-epbx n = 122 Epoetin alfa n = 122
Any treatment-emergent AE, n (%) 85 (69.7) 86 (70.5)
 Nausea 10 (8.2) 8 (6.6)
 Pyrexia 8 (6.6) 4 (3.3)
 Fall 8 (6.6) 3 (2.5)
 Dizziness 3 (2.5) 9 (7.4)
 Injection-site pain 3 (2.5) 8 (6.6)

AE, adverse event.